Full-Thickness Macular Hole and Symptomatic Vitreomacular Adhesion: Comparison of Visual Results in Patients Receiving Pars Plana Vitrectomy in One Eye and Ocriplasmin in the Fellow Eye
Restricted accessResearch articleFirst published online September, 2019
Full-Thickness Macular Hole and Symptomatic Vitreomacular Adhesion: Comparison of Visual Results in Patients Receiving Pars Plana Vitrectomy in One Eye and Ocriplasmin in the Fellow Eye
This article compares bilateral visual outcomes in patients receiving a vitrectomy in one eye for a full-thickness macular hole (FTMH) who also received ocriplasmin treatment in the fellow eye for symptomatic vitreomacular adhesion (VMA).
Methods:
This was a multicenter, retrospective study to assess the difference in best-corrected visual acuity (BCVA) in patients receiving a vitrectomy in the eye with an FTMH and ocriplasmin treatment for the fellow eye with symptomatic VMA but no FTMH. Patients initially received either a single injection of ocriplasmin 0.125 mg for symptomatic VMA or a vitrectomy for FTMH. After the first eye was stable following the initial treatment option, the second eye was treated with the opposite modality. BCVA was measured at baseline, month 3, and month 6, with up to 2 years of additional follow-up.
Results:
Thirty-six eyes (18 patients) were included in the analysis. Eyes that underwent a vitrectomy for FTMH had a mean baseline BCVA of 20/123 and a final BCVA of 20/53. Eyes receiving ocriplasmin treatment for VMA had a mean baseline BCVA of 20/49 and a final BCVA of 20/33. The median time between the 2 treatments was 5.5 months. Eyes receiving ocriplasmin had a median time to VMA resolution of 4 weeks.
Conclusions:
Treatment with ocriplasmin showed successful resolution of VMA and improvement in BCVA, obviating the need for vitrectomy. The current study provides a framework for the treatment of patients with a current FTMH in one eye and VMA without an FTMH in the contralateral eye.
García-LayanaAGarcía-ArumiJRuiz-MorenoJMArias-BarquetLCabrera-LópezFFigueroaMS. A review of current management of vitreomacular traction and macular hole[published online March 3, 2015]. J Ophthalmol. 2015;2015:809640. doi:10.1155/2015/809640
2.
StalmansPDukerJSKaiserPKet al.OCT-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina. 2013;33(10):2003–2011. doi:10.1097/IAE.0b013e3182993ef8
3.
SteelDHLoteryAJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond). 2013;27(suppl 1):S1–S21. doi:10.1038/eye.2013.212
4.
JohnVJFlynnHWJrSmiddyWEet al.Clinical course of vitreomacular adhesion managed by initial observation. Retina. 2014;34(3):442–446. doi:10.1097/IAE.0b013e3182a15f8b
5.
ShaoLWeiW. Vitreomacular traction syndrome. Chin Med J (Engl). 2014;127(8):1566–1571. doi:10.3760/cma.j.issn.0366-6999.20140211
6.
EzraE. Idiopathic full thickness macular hole: natural history and pathogenesis. Br J Ophthalmol. 2001;85(1):102–108. doi:10.1136/bjo.85.1.102
7.
Darian-SmithEHowieARAllenPLVoteBJ. Tasmanian macular hole study: whole population-based incidence of full thickness macular hole. Clin Exp Ophthalmol. 2016;44(9):812–816. doi:10.1111/ceo.12801
8.
ForsaaVALindtjørnBKvaløyJTFrøysteinTKrohnJ. Epidemiology and morphology of full-thickness macular holes. Acta Ophthalmol. 2018;96(4):397–404. doi:10.1111/aos.13618
9.
McCannelCAEnsmingerJLDiehlNNHodgeDN. Population-based incidence of macular holes. Ophthalmology. 2009;116(7):1366–1369. doi:10.1016/j.ophtha.2009.01.052
10.
DukerJSKaiserPKBinderSet al.The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120(12):2611–2619. doi:0.1016/j.ophtha.2013.07.042
EzraEWellsJAGrayRHet al.Incidence of idiopathic full-thickness macular holes in fellow eyes: a 5-year prospective natural history study. Ophthalmology. 1998;105(2):353–359. doi:10.1016/S0161-6420(98)93562-X
BronsteinMATrempeCLFreemanHM. Fellow eyes of eyes with macular holes. Am J Ophthalmol. 1981;92(6):757–761. doi:10.1016/s0002-9394(14)75625-9
15.
GuyerDRde BustrosSDiener-WestMFineSL. Observations on patients with idiopathic macular holes and cysts. Arch Ophthalmol. 1992;110(9):1264–1268. doi:10.1001/archopht.1992.01080210082030
16.
TrempeCLWeiterJJFurukawaH. Fellow eyes in cases of macular hole. Biomicroscopic study of the vitreous. Arch Ophthalmol. 1986;104(1):93–95. doi:10.1001/archopht.1986.01050130103031
17.
MorganCMSchatzH. Idiopathic macular holes. Am J Ophthalmol. 1985;99(4):437–444. doi:10.1016/0002-9394(85)90011-x
18.
McDonnellPJFineSLHillisAI. Clinical features of idiopathic macular cysts and holes. Am J Ophthalmol. 1982;93(6):777–786. doi:10.1016/0002-9394(82)90474-3
19.
JamesMFemanSS. Macular holes. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1980;215(1):59–63. doi.org/10.1007/BF00413397
20.
AabergTMBlairCJGassJD. Macular holes. Am J Ophthalmol. 1970;69(4):555–562. doi:10.1016/0002-9394(70)91620-x
21.
CrollLJCrollM. Hole in the macula. Am J Ophthalmol. 1950;33(2):248–253. doi:10.1016/0002-9394(50)90844-0
22.
JaycockPDBunceCXingWet al.Outcomes of macular hole surgery: implications for surgical management and clinical governance. Eye (Lond). 2005;19(8):879–884. doi:10.1038/sj.eye.6701679
23.
SharmaPJuhnAHoustonSKet al.Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol. 2015;159(5):861–867.e862. doi:10.1016/j.ajo.2015.01.034
24.
StefaniniFRMaiaMFalabellaPet al.Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion. Clin Ophthalmol. 2014;8:847–856. doi:10.2147/OPTH.S32274
25.
KimJWFreemanWRAzenSPel-HaigWKleinDJBaileyIL. Prospective randomized trial of vitrectomy or observation for stage 2 macular holes. Vitrectomy for Macular Hole Study Group. Am J Ophthalmol. 1996;121(6):605–614. doi:10.1016/s0002-9394(14)70625-7
26.
HikichiTYoshidaATrempeCL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119(1):55–61. doi:10.1016/s0002-9394(14)73813-9
27.
OdrobinaDMichalewskaZMichalewskiJDzięgielewskiKNawrockiJ. Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography. Retina. 2011;31(2):324–331. doi:10.1097/IAE.0b013e3181eef08c
28.
StalmansPBenzMSGandorferAet al.MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606–615. doi:10.1056/NEJMoa1110823
29.
HallerJAStalmansPBenzMSet al.MIVI-TRUST Study Group. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology. 2015;122(1):117–122. doi:10.1016/j.ophtha.2014.07.045
30.
DugelPUTolentinoMFeinerLKozmaPLeroyA. Results of the 2-year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) randomized trial. Ophthalmology. 2016;123(10):2232–2247. doi:10.1016/j.ophtha.2016.06.043
31.
StalmansP. Best Rx for vitreomacular traction: ocriplasmin. Paper presented at: American Academy of Ophthalmology (AAO) Annual Meeting; October 15-18, 2016; Chicago, IL.
AlmeidaDRChinEKRahimKFolkJCRussellSR. Factors associated with spontaneous release of vitreomacular traction. Retina. 2015;35(3):492–497. doi:10.1097/IAE.0000000000000346
34.
CodenottiMIulianoLFogliatoGQuerquesGBandelloF. A novel spectral-domain optical coherence tomography model to estimate changes in vitreomacular traction syndrome. Graefes Arch Clin Exp Ophthalmol. 2014;252(11):1729–1735. doi:10.1007/s00417-014-2645-z
35.
DimopoulosSBartz-SchmidtKUGeliskenFJanuschowskiKZiemssenF. Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?Br J Ophthalmol. 2015;99(3):350–353. doi:10.1136/bjophthalmol-2014-304961
36.
TheodossiadisGPetrouPEleftheriadouMMoustakasALDatserisITheodossiadisP. Focal vitreomacular traction: a prospective study of the evolution to macular hole: the mathematical approach. Eye (Lond). 2014;28(12):1452–1460. doi:10.1038/eye.2014.223
37.
TheodossiadisGPChatziralliIPSergentanisTNDatserisITheodossiadisPG. Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2015;253(9):1425–1435. doi:10.1007/s00417-014-2826-9
38.
TheodossiadisGPGrigoropoulosVGTheodoropoulouSDatserisITheodossiadisPG. Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography. Am J Ophthalmol. 2014;157(4):842–851e841. doi:10.1016/j.ajo.2014.01.011
39.
ZhangZDongFZhaoCet al.Natural course of vitreomacular traction syndrome observed by spectral-domain optical coherence tomography. Can J Ophthalmol. 2015;50(2):172–179. doi:10.1016/j.jcjo.2014.12.003
40.
TzuJHJohnVJFlynnHWJret al.Clinical course of vitreomacular traction managed initially by observation. Ophthalmic Surg Lasers Imaging Retina. 2015;46(5):571–576. doi:10.3928/23258160-20150521-09
41.
StalmansP. A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol. 2016;254(4):617–628. doi:10.1007/s00417-016-3294-1
42.
WuLZasMBerrocalMHet al.Anatomical and functional outcomes of symptomatic idiopathic vitreomacular traction: a natural history study from the Pan American Collaborative Retina Study Group. Retina. 2016;36(10):1913–1918. doi:10.1097/IAE.0000000000001015
SmiddyWEMichelsRGGlaserBMdeBustrosS. Vitrectomy for macular traction caused by incomplete vitreous separation. Arch Ophthalmol. 1988;106(5):624–628. doi:10.1001/archopht.1988.01060130678025
45.
SonmezKCaponeAJrTreseMTWilliamsGA. Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina. 2008;28(9):1207–1214. doi:10.1097/IAE.0b013e31817b6b0f
46.
SteinJDZacksDNGrossmanDGrabeHJohnsonMWSloanFA. Adverse events after pars plana vitrectomy among Medicare beneficiaries. Arch Ophthalmol. 2009;127(12):1656–1663. doi:10.1001/archophthalmol.2009.300
47.
CherfanGMMichelsRGde BustrosSEngerCGlaserBM. Nuclear sclerotic cataract after vitrectomy for idiopathic epiretinal membranes causing macular pucker. Am J Ophthalmol. 1991;111(4):434–438. doi:10.1016/s0002-9394(14)72377-3
48.
MelbergNSThomasMA. Nuclear sclerotic cataract after vitrectomy in patients younger than 50 years of age. Ophthalmology. 1995;102(10):1466–1471. doi: 10.1016/S0161-6420(95)30844-5
49.
ThompsonJTGlaserBMSjaardaRNMurphyRP. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol. 1995;119(1):48–54. doi:10.1016/s0002-9394(14)73812-7
50.
Van EffenterreGAmelineBCampinchiFQuesnotSLe MerYHautJ. Is vitrectomy cataractogenic? Study of changes of the crystalline lens after surgery of retinal detachment [article in French]. J Fr Ophtalmol. 1992;15(8-9):449–454.
51.
ChengLAzenSPEl-BradeyMHet al.Duration of vitrectomy and postoperative cataract in the Vitrectomy for Macular Hole Study. Am J Ophthalmol. 2001;132(6):881–887. doi:10.1016/s0002-9394(01)01263-6
52.
HolekampNMShuiYBBeebeDC. Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol. 2005;139(2):302–310. doi:10.1016/j.ajo.2004.09.046
53.
ShimadaYSenoYMizuguchiTTanikawaAHoriguchiM. Patient adherence to the face-down positioning after macular hole surgery. Clin Ophthalmol. 2017;11:1099–1104. doi:10.2147/OPTH.S135144
54.
HahnPChungMMFlynnHWJret al.Safety profile of ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences. Retina. 2015;35(6):1128–1134. doi:10.1097/IAE.0000000000000519
55.
KaiserPKKampikAKuppermannBDGirachARizzoSSergottRC. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina. 2015;35(6):1111–1127. doi:10.1097/IAE.0000000000000448
56.
BirchDGBenzMSMillerDMet al.Evaluation of full-field electroretinogram reductions after ocriplasmin treatment: results of the OASIS Trial ERG Substudy. Retina. 2018;38(2):364–378. doi:10.1097/IAE.0000000000001536
